Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

BACKGROUND: Cognitive impairment is common in multiple sclerosis (MS), with cognitive processing speed being the most frequently affected domain. OBJECTIVE: Examine the effects of daclizumab beta versus intramuscular (IM) interferon (IFN) beta-1a on cognitive processing speed as assessed by Symbol D...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedict, Ralph HB, Cohan, Stanley, Lynch, Sharon G, Riester, Katherine, Wang, Ping, Castro-Borrero, Wanda, Elkins, Jacob, Sabatella, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971365/
https://www.ncbi.nlm.nih.gov/pubmed/28485186
http://dx.doi.org/10.1177/1352458517707345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971365/
https://www.ncbi.nlm.nih.gov/pubmed/28485186
http://dx.doi.org/10.1177/1352458517707345

Ejemplares similares